bluebird bio Inc (NASDAQ:BLUE) Insider David Davidson Sells 7,660 Shares

bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 7,660 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $129.47, for a total transaction of $991,740.20. Following the transaction, the insider now directly owns 38,946 shares in the company, valued at approximately $5,042,338.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Davidson also recently made the following trade(s):

  • On Monday, May 6th, David Davidson sold 6,360 shares of bluebird bio stock. The shares were sold at an average price of $138.95, for a total transaction of $883,722.00.

NASDAQ:BLUE opened at $133.98 on Friday. bluebird bio Inc has a 12 month low of $87.49 and a 12 month high of $183.60. The company has a market capitalization of $7.33 billion, a price-to-earnings ratio of -12.54 and a beta of 2.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.31 and a current ratio of 9.31. The company has a 50 day moving average price of $123.52.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.79) by ($0.20). bluebird bio had a negative net margin of 1,184.01% and a negative return on equity of 34.01%. The firm had revenue of $12.47 million during the quarter, compared to the consensus estimate of $15.49 million. During the same period in the prior year, the business earned ($2.31) EPS. The company’s revenue for the quarter was down 21.9% compared to the same quarter last year. As a group, research analysts expect that bluebird bio Inc will post -12.24 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can raised its position in shares of bluebird bio by 0.3% in the first quarter. Bank of Montreal Can now owns 42,169 shares of the biotechnology company’s stock valued at $6,634,000 after purchasing an additional 114 shares during the period. Clearbridge Investments LLC raised its position in shares of bluebird bio by 18.2% in the first quarter. Clearbridge Investments LLC now owns 839 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 129 shares during the period. Woodstock Corp raised its position in shares of bluebird bio by 2.2% in the first quarter. Woodstock Corp now owns 6,408 shares of the biotechnology company’s stock valued at $1,008,000 after purchasing an additional 137 shares during the period. Advisor Group Inc. raised its position in shares of bluebird bio by 15.5% in the fourth quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 169 shares during the period. Finally, Icon Wealth Partners LLC bought a new position in shares of bluebird bio in the first quarter valued at approximately $31,000.

Several equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Maxim Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a research report on Tuesday, June 18th. Wedbush reaffirmed an “outperform” rating and set a $124.00 price objective on shares of New Relic in a research report on Wednesday, May 15th. BidaskClub raised shares of Northrim BanCorp from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. Finally, William Blair reaffirmed an “outperform” rating on shares of Activision Blizzard in a research report on Friday, May 3rd. Ten analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $162.49.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Featured Article: Real Estate Investment Trust (REIT) ETF

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.